IP Library Granted Patent US 8,444,633
Granted Patent B2
US 8,444,633 · App. 12/104,401 · Granted May 21, 2013

System and method for altering internal stress distributions to reshape a material

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,444,633
App. No.
12/104,401
Granted
May 21, 2013
Kind
B2
Abstract

A system and method for altering the configuration of a transparent material (e.g. the cornea of an eye) requires identifying local stress distribution patterns inside the material. These patterns are then used to define boundary (interface) surfaces between volumes within the material. In operation, a laser unit performs Laser Induced Optical Breakdown (LIOB) along selected boundary surfaces to disrupt stress distribution patterns between volumes of the material that are separated from each other by the boundary surface. This LIOB allows an externally applied force to thereby alter the configuration of the material.

Claims (32)

1. A method for altering a configuration of a transparent material while the material is being subjected to an external force, the method comprising the steps of:

measuring a topography for a surface of the material; comparing the topography with a reference datum to identify a deviation between the topography and the reference datum, the deviation selected from a group of deviations consisting of a surface bulge and a surface depression;

identifying a volume of material underlying the deviation, wherein the underlying volume defines a boundary surface surrounding a stress distribution;

laser cutting the material on a selected portion of the boundary surface of the underlying volume to disrupt the stress distribution causing the deviation on the selected boundary surface between material in the underlying volume and material adjacent thereto; and

allowing the external force to alter the configuration of the transparent material in response to the cutting step.

2. A method as recited in claim 1 wherein the transparent material is a cornea of an eye.

3. A method as recited in claim 2 wherein the surface of the material is an anterior surface of the cornea.

4. A method as recited in claim 2 wherein the external force is caused by an intraocular pressure in the eye.

5. A method as recited in claim 2 wherein the reference datum is a substantially spherical surface.

6. A method as recited in claim 1 wherein the cutting step is accomplished using a femtosecond laser to cause Laser Induced Optical Breakdown (LIOB) of material.

7. A method as recited in claim 6 wherein the LIOB is accomplished over a substantially cylindrical surface.

8. A method as recited in claim 6 wherein the LIOB is accomplished over a substantially planar surface.

9. A method as recited in claim 6 wherein an extent of LIOB in the material is based on characteristics of the deviation.

10. A method for altering a configuration of a transparent material while the material is being subjected to an external force, the method comprising the steps of:

identifying a plurality of stress distributions surrounded by a respective plurality of different boundary surfaces within the material;

comparing each stress distribution with a reference datum to identify a deviation therebetween, the deviation selected from a group of deviations consisting of a surface bulge and a surface depression;

selecting a boundary surface of a volume of material underlying the deviation, based on the comparing step;

laser cutting material over the selected surface to disrupt the stress distribution causing the deviation; and

allowing the external force to alter the configuration of the transparent material in response to the cutting step.

11. A method as recited in claim 10 wherein the transparent material is a cornea of an eye.

12. A method as recited in claim 10 wherein the cutting step is accomplished using a femtosecond laser to cause Laser Induced Optical Breakdown (LIOB) of material and the extent of LIOB in the material is based on dimensional characteristics of the deviation.

13. A method as recited in claim 12 wherein the LIOB is accomplished over a substantially cylindrical surface.

14. A method as recited in claim 12 wherein the LIOB is accomplished over a substantially planar surface.

15. A method as recited in claim 10 wherein the reference datum is a base stress distribution calculated to configure the material with a predetermined shape.

16. A device for altering a configuration of a transparent material while the material is being subjected to an external force, the device comprising:

a diagnostic means for identifying a plurality of stress distributions surrounded by a respective plurality of different surfaces within the material;

a computer means for selecting a surface and comparing the stress distribution on the selected surface with a reference datum to identify a deviation therebetween, the deviation selected from a group of deviations consisting of a surface bulge and a surface depression, the surface being a boundary surface of a volume of material underlying the deviation; and

a laser means for cutting material over the selected surface, to disrupt the stress distribution causing the deviation and alter the configuration of the transparent material by allowing the material to react to the external force.

17. A device as recited in claim 16 wherein the diagnostic means is a topography sensor for measuring a topography for a surface of the material.

18. A device as recited in claim 17 wherein the reference datum is a base stress distribution calculated to configure the material with a predetermined shape.

19. A device as recited in claim 17 wherein the laser means is a femtosecond laser to cause Laser Induced Optical Breakdown (LIOB) of material.

20. A device as recited in claim 19 wherein an extent of LIOB in the material is based on characteristics of the deviation.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →